title: [Radically resected pancreatic cancer and adjuvant treatment. A review of the literature].
abstract: Adjuvant therapy represents the gold standard treatment for radically resected pancreatic cancer. Results from randomized clinical trials confirmed the efficacy of adjuvant therapy for pancreatic cancer but did not define what is the "right choice" in terms of type of antiblastic drug (among gemcitabine, 5-fluorouracil or other drugs), role of polychemotherapy and chemoradiotherapy. The objective of our study was to evaluate the efficacy and toxicity of adjuvant chemotherapy and chemoradiotherapy for radically resected pancreatic cancer through a systematic review of literature data, emphasizing the benefits regarding overall survival, disease-free survival and toxicity.
authors.affiliation: Ospedale Civile Infermi, Rimini. f.drudi1@virgilio.it
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Drudi
authors.forename: Davide
authors.initials: D
authors.lastname: Tassinari
authors.forename: Jacopo
authors.initials: J
authors.lastname: Giuliani
authors.forename: Claudio
authors.initials: C
authors.lastname: Ridolfi
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Gianni
authors.forename: Emiliano
authors.initials: E
authors.lastname: Tamburini
authors.forename: Manuela
authors.initials: M
authors.lastname: Fantini
authors.forename: Carlotta
authors.initials: C
authors.lastname: Santelmo
authors.forename: Eleonora
authors.initials: E
authors.lastname: Barzotti
authors.forename: Nadia
authors.initials: N
authors.lastname: Lotti
authors.forename: Alberto
authors.initials: A
authors.lastname: Ravaioli
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D059248:Chemoradiotherapy; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D010180:Pancreatectomy / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery* / Q000628:therapy; D017410:Practice Guidelines as Topic; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D016019:Survival Analysis; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil; D000093542:Gemcitabine